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Stability-indicating HPLC-PDA assay for simultaneous 
determination of paracetamol, thiamine and pyridoxal phosphate 
in tablet formulations
With the increased number of multi-drug formulations, 
there is a need to develop new methods for simultaneous 
determinations of drugs. A precise, accurate and reliable 
liquid chromatographic method was developed for simul-
taneous determination of paracetamol, thiamine, and pyri-
doxal phosphate in pharmaceutical formulations. Separa-
tion of analytes was carried out with an Agilent Poroshell 
C18 column. A mixture of ammonium phosphate buffer 
(pH = 3.0), acetonitrile and methanol in the ratio of 86:7:7 
(V/V/V) was used as the mobile phase pumped at a flow rate 
of 1.8 mL min–1. Detection of all three components, impuri-
ties and degradation products was performed at the selected 
wavelength of 270 nm. The developed method was vali-
dated in terms of linearity, specificity, precision, accuracy, 
LOD and LOQ as per ICH guidelines. Linearity of the de-
veloped method was found in the range 17.5–30 µg mL–1 for 
thiamine, 35–60 µg mL–1 for pyridoxal phosphate and 87.5–
150 µg mL–1 for paracetamol. The coefficient of determina-
tion was ≥ 0.9981 for all three analytes. The proposed HPLC 
method was found to be simple and reliable for the routine 
simultaneous analysis of paracetamol, thiamine and pyri-
doxal phosphate in tablet formulations. Complete separa-
tion of analytes in the presence of degradation products 
indicated selectivity of the method.
Keywords: paracetamol, thiamine, pyridoxine phosphate, 
degradation, HPLC-PDA
With advancement in research and development in the pharmaceutical industry, the 
role and production of multicomponent drug formulations is increasing steadily. Recent 
advances in pharmaceutical sciences have proven that the one drug-one target lock and 
key model is limited (1). In many complicated and refractory diseases hardly any single 
drug has shown satisfactory benefits. However, using a combination of drugs has offered 
more satisfactory results (2). Multidrug pharmaceutical fixed dose combinations contain 
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different active pharmaceutical ingredients (API) for the treatment of pain; the compo-
nents mostly include aspirin and paracetamol with codeine, barbiturates, caffeine, deriva-
tives of pyrazolones, pentazocine and vitamins that can enhance the pharmacological 
 effectiveness of these fixed dose combinations (3). The different API components have 
different modes of action; they sometimes act as synergists with more efficiency. In multi-
drug fixed dose combinations each API is usually present in a dose lower than in the 
 single-component formulation, lowering the organ burden (4). Paracetamol (acetamino-
phen, N-acetyl-p-aminophenol), thiamine (2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-
4-methyl-1,3-thiazol-3-ium-5-yl, B1] ethanol, C12H17N4OS+) and pyridoxal phosphate 
([(4-formyl-5-hydroxy-6-methylpyridin-3-yl)methoxy] phosphonic acid, C8H10NO6P, B6) 
are the analytes of interest in the mixture in our research (5–7). 
A literature survey revealed that different analytical methods were available for the 
estimation of paracetamol, individually or in fixed dose combinations other than vitamins 
B1 and B6, by various methods including voltammetry, LC-MS-MS, micellar electrokinetic 
capillary chromatography and flow injection solid phase spectrometry (8–10). It was also 
found that vitamins B1 and B6 were estimated individually or in pharmaceutical combina-
tions other than paracetamol using spectroscopic and chromatographic techniques coupled 
to various detectors such as UV-visible, fluorometric and electrochemical ones (11–16).
To the best of our knowledge, several RP-HPLC methods are available for the estima-
tion of paracetamol, thiamine and pyridoxal phosphate (Fig. 1), individually or in combina-
tion with other drugs in fixed dose pharmaceutical formulations but no stability indicating 
assay method has been reported (17–21). The present research is aimed at developing a 
rapid, sensitive and stability indicating liquid chromatographic (HPLC) method for the 
simultaneous determination of paracetamol, thiamine, and pyridoxal phosphate. The pro-
posed HPLC method was validated according to ICH guidelines and forced degradation 
studies were performed to show the stability-indicating nature of the method (22–24).
EXPERIMENTAL
Chemicals and reagents
Paracetamol (PRML), thiamine (B1), and pyridoxal phosphate (B6) working standards 
were donated by Schazoo Pharmaceutical Laboratories Ltd. (Pakistan). Diammonium 
 hydrogen phosphate and phosphoric acid (85 %) were obtained from Sigma Aldrich, USA. 
Methanol and acetonitrile were purchased from Merck, Germany. In experimental work, 
Fig. 1. Chemical structures of: a) thiamine, b) pyridoxal phosphate, and c) paracetamol.
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distilled water (18 µS cm–1) was used, prepared in our own lab using the GenPure water 
system (Thermo Scientific, USA). The solvents and chemicals used during analysis were of 
HPLC grade. Multi drug formulations in tablet form, containing paracetamol, thiamine, 
and pyridoxal phosphate were collected from the local market shelves (Neuro Bedoxine 
Plus tablets, each film coated tablet containing: vitamin B1 50 mg, vitamin B6 100 mg, vi-
tamin B12 100 mg, paracetamol 250 mg, Schazoo Pharmaceutical Laboratories, Pakistan) 
in Lahore, the capital city of Pakistan.
Chromatography
An LC-20 liquid chromatograph (Shimadzu, Japan) with diode array detector (SPD-
M20A), online degasser (DGU-20A5) equipped with Agilent Poroshell C18 column (5 µm, 
4.6 × 250 mm) was employed to separate the components. A mixture of ammonium phos-
phate buffer (pH = 3.0), acetonitrile and methanol, 86:7:7 volume ratio, was used as the 
mobile phase. Mobile phase was sonicated for 10 min to degas before use. The finally se-
lected optimized conditions were as follows: injection volume 10 µL, adjusted flow rate 1.8 
mL min–1, column temperature 40 °C, API detection at 270 nm. Standard and sample solu-
tions were filtered using a nylon filter (0.45 µm, Sartorius, Germany) before analysis.
Standard and working solutions 
Standard stock solutions (1000 µg mL–1) of PRML, B1 and B6 were prepared in methanol 
and sonicated for 10 min. The stock standard solution was diluted with the mobile phase 
to prepare individual working standard solutions. Amounts of 250 mg PRML, 50 mg B1 
and 100 mg B2 were dissolved in methanol to a 100 mL volume; 5.0 mL of the above solu-
tion was diluted with the mobile phase to 100 mL to prepare a mixed standard solution 
with the final concentration of 125 µg mL–1 PRML, 25 µg mL–1 B1 and 50 µg mL–1 B6.  
Sample preparation
Ten tablets (Neuro Bedoxine Plus tablet containing 250 mg PRML, 50 mg B1 and 100 mg 
B6, Schazoo Pharmaceutical Laboratories, Pakistan) were ground and the mass equivalent 
to one tablet was dissolved in methanol and the volume was made up to 100 mL with metha-
nol. The working sample solution was prepared by 20-fold dilution with the mobile phase.
Forced degradation studies
Forced degradation studies were performed with standard solutions of PRML, B1 and 
B6 having final concentrations of 125, 25, 50 µg mL–1, resp. Ten (10.0) mL of each standard 
solution was added into separate measuring flasks and treated with 10.0 mL of NaOH (0.1 
mol L–1), HCl (0.1 mol L–1), and H2O2 (15 %, V/V) for 12 h to study the basic and acidic hy-
drolysis and oxidative stress, resp. Thermal and photolytic stress studies were performed 
after keeping the solid tablets at 100 °C for 6 h and exposing them to UV-light (254 nm) for 
24 h, resp.
Method validation 
Validation of the developed method included precision, linearity, specificity, accuracy, 
limit of detection (LOD), limit of quantification (LOQ) and robustness (22). Conformity of 
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chromatographic parameters, including the selectivity factor, tailing factor, resolution, 
theoretical plates, were also assessed while robustness was checked by deliberate changes 
in chromatographic conditions such as the flow rate (± 0.1 mL min –1), column temperature 
(± 2 °C), wavelength (± 2 nm) and pH (± 0.1). 
For accuracy of the proposed method, the tablet formulation was spiked with known 
amounts of API at 70 % (175 mg PRML, 35 mg B1 and 70 mg B6), 100 % (250 mg PRML, 50 
mg B1 and 100 mg B6) and 120 % (300 mg PRML, 60 mg B1 and 120 mg B6) and analysis 
was performed after 20-fold dilution with the mobile phase. Percentage recoveries of 
PRML, B1 and B6 were assessed in triplicate and the results are presented as mean ± SEM. 
Precision of the proposed method was checked by injecting the standard solutions of 
PRML, B1 and B6 at three concentration levels (70, 100 and 120 % as defined in recovery 
studies). To measure intra-day and inter-day precision, standard solutions were injected 
on the same day and on three consecutive days, resp.
Linearity of the proposed method was determined for PRML, B1 and B6 using stan-
dard solutions having concentrations 87–150 µg mL–1 PRML, 17.5–30 µg mL–1 B1 and 35–60 
µg mL–1 B6 and injected in triplicate to construct the calibration curve. LOD and LOQ were 
also determined from the calibration curves as 3.3 σ/S and 10 σ/S, resp., with σ being the 
standard deviation and S the slope of the regression line.
Analysis of a placebo solution including gelatin (40.0 mg), lactose (14.0 mg), Avicel 
(102.0 mg), primogel (25.0 mg), talc (15.0 mg) and magnesium stearate (4.0 mg) was made 
to check the specificity of the proposed HPLC method. Specificity was also measured by 
forced degradation studies.
Solution stability
Stability of the sample and standard solutions was estimated against freshly prepared 
standard solutions at intervals of 12, 24 and 48 h at room temperature.
RESULTS AND DISCUSSION
Optimization of chromatographic conditions
The first step in method development was the selection of appropriate wavelengths 
for different compounds having different wavelength absorption maxima. A spectrum in 
the range of 200–400 nm showed acceptable absorbance at a wavelength of 270 nm for each 
analyte (Fig. 2) under investigation, which was chosen for quantification.
Optimization of the mobile phase was performed with a solution containing water 
and acetonitrile or methanol. It was observed that peaks of these three analytes were not 
completely separated. Different combinations of methanol, acetonitrile and phosphate 
buffer of different pH (3.0, 4.0, 5.0, 6.0, and 7.0) were then tested to optimize the chromato-
graphic conditions including the tailing factor, resolution, theoretical plates and retention 
times. Different C18 and C8 reversed phase columns were also tested including Venusil XBP 
C8, Hypersil ODS C18, ACE C8 and Agilent Poroshell C18 (Table I). Agilent Poroshell C18 
(5 µm, 4.6 × 250 mm) reversed phase column with a mobile phase comprising phosphate 
buffer (pH = 3.0)/methanol/acetonitrile (86:7:7, V/V/V) pumped at a flow rate of 1.8 mL min–1 
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afforded the best separation of PRML, B1 and B6. The respective retention times found 
were 1.89, 2.41 and 6.29 min. Chromatographic parameters obtained under final conditions 
are summarized in Table II.
Method validation 
For linearity assessment, six concentrations (n = 3) in the range of 70–120 % of the label 
claim of B1, B6 and PRML were employed (Table III). Coefficients of determination (R2) 
were ≥ 0.998. The results demonstrate linearity of the developed method over the specified 
ranges. The placebo sample, namely excipients, showed no peak. Therefore, the proposed 
method is specific for APIs in the tablet, as shown in the chromatogram (Fig. 3).
Accuracy of the proposed method was estimated by recovery experiments. Recovery 
values (Table IV) for B1, B6 and PRML ranged from 100.4–100.6, 100.2–101.2 and 99.3–99.6 
%, resp.
Table I. Stationary phase testing
Column Analyte Rs Tf α N
Hypersil ODS C18



































































α – selectivity factor, B1 and B6 – vitamins B1 and B6, N – number of theoretical plates per meter, PRML – para-
cetamol, Rs – chromatographic resolution, Tf – tailing factor
Fig. 2. Overlaid spectra of thiamine (B1), pyridoxal phosphate (B6), and paracetamol (PRML). mAU – 
milli absorbance units.
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Table II. Chromatographic parameters of the optimized HPLC procedure on the Agilent Poroshell C18 column
Parameter B1 B6 PRML
Retention time (tR, min) 1.89 2.41 6.29
Tailing factor (Tf) 1.48 1.39 1.52
Chromatographic resolution (RS) – 4.18 17.18
Separation factor (α) – – 8.75
Theoretical plates per meter (N) 1316 1497 4633
Retention time RSD (%) 0.003 0.002 0.002
B1 and B6 – vitamins B1 and B6, PRML – paracetamol
Table III. Regression and limiting values data for vitamins B1 and B6 and PRML
Parameter B1 B6 PRML
Linearity range (µg mL–1 ) 17.5–30.0 35.0–0.0 87.0–150.0
Slope (mV mL mg–1) 81930 34352 52895
Intercept (mV) –3645 –3145 23562
Standard error of slope (mV mL mg–1) 952.8 386.3 689.8
Standard error of intercept (mV) 22991 18646 83070
Coefficient of determination (R2) 0.9995 0.9995 0.9993
Limit of detection (LOD, µg mL–1 ) 0.40 0.78 2.26
Limit of quantification (LOQ, µg mL–1 ) 1.20 2.33 6.77
B1 and B6 – vitamins B1 and B6, PRML – paracetamol
Table IV. Accuracy studies of vitamins B1 and B6 and PRML by the new HPLC method
Analyte Spiked concentration (µg mL–1 )
Concentration found 
 (µg mL–1, mean ± SEM; RSD, %)a
Recovery  
(%)
17.5 17.6 ± 0.4; 0.6 100.4
B1 25.0 25.1 ± 0.5; 0.9 100.6
30.0 30.2 ± 0.3; 0.4 100.6
35.0 35.3 ± 0.4; 0.6 100.9
B6 50.0 50.1 ± 0.5; 0.9 100.2
60.0 60.7 ± 0.3; 0.4 101.2
87.0 86.4 ± 0.4; 0.6  99.3
PRML 125.0 124.4 ± 0.5; 0.9  99.6
150.0 149.4 ± 0.25; 0.5  99.6
B1 and B6 – vitamins B1 and B6, PRML – paracetamol
a n = 3
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Intra-day and inter-day precision were assessed on the same day and on three con-
secutive days, resp. The results were within acceptable limits (RSD < 2 %), as shown in 
Table V.
Fig. 3. Typical HPLC chromatograms of: a) mobile phase, b) placebo sample, c) standard mixture (125 
µg mL–1 PRML, 25 µg mL–1 B1 and 50 µg mL–1 B6), and d) Neurobedoxine plus tablets (125 µg mL–1 
PRML, 25 µg mL–1 B1 and 50 µg mL–1 B6) after dilution with the mobile phase. B1 and B6 – vitamins 
B1 and B6, PRML – paracetamol.







 (µg mL–1, mean ± 
SEM; RSD, %)a
Concentration found 
 (µg mL–1, mean ± SEM; RSD, %)a
Day 1 Day 2 Day 3
17.5 17.6 ± 0.2; 0.3 17.8 ± 0.6; 1.0 17.3 ± 0.5; 0.8 17.6 ± 0.3; 0.5
B1 25.0 25.3 ± 0.3; 0.5 25.2 ± 0.5;0.8 24.8 ± 0.5; 0.8 25.3 ± 0.7; 1.3
30.0 29.9 ± 0.3; 0.5 30.7 ± 0.3; 0.5 30.4 ± 0.6; 1.0 30.1 ± 0.2; 0.4
35.0 35.4 ± 0.5;0.8 35.6 ± 0.7; 1.2 35.3 ± 0.7; 1.2 35.2 ± 0.5; 0.8
B6 50.0 50.8 ± 0.5; 0.9 49.8 ± 0.6; 1.1 50.8 ± 0.8; 1.4 50.8 ± 0.7; 1.1
60.0 61.3 ± 0.5; 0.8 61.7 ± 0.5; 0.9 60.6 ± 0.9; 1.4 59.6 ± 0.5; 0.9
87.0 89.3 ± 0.1; 0.2 88.2 ± 0.9; 1.5 88.2 ± 0.9; 1.4 88.6 ± 0.6; 1.0
PRML 125.0 128.4 ± 0.7; 1.2 127.4 ± 0.5; 0.9 126.8 ± 0.6; 0.9 128.1 ± 0.3; 0.5
150.0 153.0 ±0.3; 0.6 153.8 ± 0.8; 1.4 150.4 ± 1.0; 1.7 152.9 ± 0.5; 0.8
B1 and B6 – vitamins B1 and B6, PRML – paracetamol
a n = 5.
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Deliberate changes in the chromatographic conditions showed no significant varia-
tion (Table VI) in the chromatographic parameters such as the tailing factor (T < 2), number 
of theoretical plates per meter (N > 2000) and resolution (Rs > 2), which demonstrated that 
the proposed HPLC method was robust.
Forced degradation
The respective chromatograms obtained during degradation studies are shown in 
Figs. 4a-e. Three major impurity peaks and two minor impurity peaks of degradation 
products were obtained. The results of degradation studies are given in Table VII. 
Under acidic stress conditions (Fig. 3a), the remaining amounts were 53.3 % B1, 88.3 % 
B6 and 60.3 % PRML. Under basic conditions, major degradation was observed in PRML 
(29.1 %). B6 was also degraded to a substantial extent, while B1 did not degrade. Two major 
impurity peaks were obtained during alkali forced degradation (Fig. 4b).
Degradation in 3 % hydrogen peroxide was found to be 5.7, 3.6 and 5.7 % for B1, B6 and 
PRML, resp. Three minor impurity peaks obtained under oxidative stress conditions are 
shown in Fig. 4c.
Under photolytic and thermal stress conditions, all three APIs, B1, B6 and PRML, were 
stable and no extra peaks were observed (Figs. 4d,e).
The proposed HPLC method was found to be specific enough for the analysis of B1, 
B6 and PRML, including degradation products during degradation studies.
Analysis of commercial samples
















Flow rate 1.9 (mL min–1) 100.3 1.86 3564 100.9 2.38 6645 99.3 6.26 7350
Flow rate 1.7 (mL min–1) 100.2 1.93 3576 100.3 2.45 6623 99.7 6.31 7324
Column temp. (45 °C) 101.3 1.92 3579 99.5 2.44 6635 101.3 6.33 7367
Column temp. (35 °C) 101.7 1.93 3591 99.9 2.39 6667 101.6 6.32 7354
Wavelength (272 nm) 100.8 1.89 3518 101.3 2.46 6645 100.7 6.34 7329
Wavelength (268 nm) 100.7 1.90 3542 101.0 2.44 6668 100.4 6.33 7366
pH 3.1 99.3 1.90 3555 100.3 2.38 6623 100.1 6.29 7365
pH 2.9 99.9 1.92 3563 100.6 2.40 6634 100.4 6.27 7325
B1 and B6 – vitamins B1 and B6, PRML – paracetamol, N – number of theoretical plates per meter
Fig. 4. Typical HPLC chromatograms under stress conditions: a) acidic, b) basic, c) oxidative, d) pho-
tolytic, and e) thermal. B1 and B6 – vitamins B1 and B6, PRML – paracetamol.
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Table VII. Force degradation studies for vitamins B1 and B6 and PRML in tablets
Stress conditions Component Assay (%) Extent of degradation
HCl (0.1 mol L–1, 12 h) B1 53.3 Substantial
B6 88.3 Substantial
PRML 60.3 Substantial
NaOH (0.1 mol L–1, 12 h) B1 98.2 None
B6 87.3 Substantial
PRML 70.9 Substantial
H2O2 (3 %, 12 h) B1 94.3 Slight
B6 97.5 None
PRML 94.3 Slight
UV light (254 nm, 24 h) B1 99.4 None
B6 98.8 None
PRML 100.2 None
Heating (70 °C, 6 h) B1 99.3 None
B6 98.9 None
PRML 99.9 None
B1 and B6 – vitamins B1 and B6, PRML – paracetamol
Table VIII. Commercial tablet assay for B1, B6 and PRML






















B1 50 50.5 ± 0.1 0.5 40.0 90.9 100.5 ± 0.2 0.6
50.0 100.9 100.3 ± 0.2 0.7
60.0 111.1 100.5 ± 0.2 0.5
B6 100 101.6 ± 0.3 0.9 80.0 181.5 99.9 ± 0.2 0.7
100.0 201.3 99.8 ± 0.2 0.5
120.0 222.8 100.5 ± 0.3 0.9
PRML 250 248.9 ± 0.7 0.9 200.0 450.1 100.3 ± 0.3 0.8
250.0 500.7 100.4 ± 0.1 0.4
300.0 551.5 100.5 ± 0.2 0.6
B1 and B6 – vitamins B1 and B6, PRML – paracetamol
a Mean  ± SEM.
b n = 10.
c Neuro Bedoxine Plus tablet label claim: 250 mg PRML, 50 mg B1 and 100 mg B6.
258
A. Ali et al.: Stability-indicating HPLC-PDA assay for simultaneous determination of paracetamol, thiamine and pyridoxal phosphate 
in tablet formulations, Acta Pharm. 69 (2019) 249–259.
 
Concentration of three APIs in the commercial tablet formulation was estimated by 
the proposed HPLC method. It was evidenced that the proposed HPLC method was pre-
cise (RSD 0.4–0.9 %) and accurate enough (recovery 99.8–100.5 %) for successful routine 
analyses (Table VIII).
CONCLUSIONS
In the literature, no stability indicating HPLC method is found available for simulta-
neous determination of paracetamol, thiamine, and pyridoxal phosphate. Stress testing 
under ICH specifications indicated that the proposed HPLC method is stability indicating 
and selective. The total run time of analysis was found to be less than 7 min. The proposed 
method showed high recovery and precision in the presence of excipients used in the for-
mulation. It might be assumed that the proposed HPLC method is simple, precise, accu-
rate, linear and sufficiently selective for routine simultaneous determination of paracetamol, 
thiamine and pyridoxal phosphate.
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